The present invention relates to a crystal form of potassium-competitive acid blockers, that is, 1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1 H- pyrrole-3-yl]- N- methyl methylamine fumaric acid salt (which is briefly referred to as a formula I) and a preparation method therefor. An X-ray powder diffraction characteristic peak thereof is shown in FIG. 1 . The crystal form that is represented by formula I, provided in present invention, is stable, has good repeatability, and is suitable for drug development.
